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MALDI-imaging mass spectrometry (MALDI-IMS) is a novel experimental 
approach to visualize the distribution of biomolecules on tissue sections [1]. Proteins, 
peptides, lipids and metabolites can be analyzed in a selective and/or highthroughput 
manner. The application of IMS allows acquisition of protein and peptide profiles, 
biomarker discovery, biomarker localization, tissue classification or cancer diagnosis 
and prognosis [1,2]. In this study we report the distribution of protease inhibitors in 
several mouse tissues, after intraperitoneal injection.  
Mice were administered twice daily with 250 mg/kg of the inhibitor(s) and they 
were sacrificed one hour after the second dose. We followed standard protocols for 
sample preparation, generation of tissue slices and analyses of the MALDI spectra [3 & 
Bruker-protocols]. The localization of the protease inhibitors and their potential 
derivatives on the tissues were analyzed and we also compared their distribution among 
the tissues. One of our goals is to investigate the differential distribution and fates of 
such molecules when administered in vivo in mice, having in mind potential 
pharmacological strategies [4]. 
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